The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
But yet we still have a sp of only 0.9p
:(
Reduces Blood Lipids
Improves Blood Flow
Reduces Blood Pressure
Prevents Heart Attack
Prevents Stroke
Prevents Deep Vein Thrombosis
Reduces the negative effects of air pollution
Reduces exercise induced inflammation
Stiffens your Johnson
Modulates your gut microbiota
Improves your memory
Reduces Women’s increased cardiovascular risks associated with menopause, pregnancy and the pill.
Reduces increased cardiovascular risks associated with Covid-19
treating a wide variety of human health conditions, beyond Fruitflow's existing established use in heart-health
What else is there?
Just need a cure for cancer and we’ll have the full set , IP would be worth £billion s imo
Does it make anyone else slightly nervous when we see By-Health starting to apply for patents on WTSE - or is it me being over sensitive.
We have the holy trinity of hearth health. Blood pressure reduction, blood lipid reduction and decreased platelet aggregation / improved blood flow. And as an added bonus, it can improve you stiffy, improve your memory and improve your gut bacteria.
Composition with effect of assisting in reducing blood fat and application thereof
Abstract
The invention relates to a composition with an auxiliary blood fat reducing effect and application thereof. In particular to application of a composition in preparing a medicine or health-care food with the effect of assisting in reducing blood fat, wherein the composition comprises water-soluble tomato concentrate and functional red rice powder. According to the invention, experimental researches show that the water-soluble tomato concentrate and the functional red rice powder have a coordination and synergism effect in the aspect of assisting blood fat reduction, and by compounding the water-soluble tomato concentrate and the functional red rice powder, the levels of triglyceride, cholesterol and low-density lipoprotein can be obviously reduced, so that an excellent effect of assisting blood fat reduction is achieved.
https://patents.google.com/patent/CN114504617A/en?q=%22water+soluble+tomato+concentrate%22&oq=%22water+soluble+tomato+concentrate%22&sort=new
Water-soluble tomato extract with function of improving memory and application thereof
Abstract
The invention discloses a water-soluble tomato extract with a function of improving memory and application thereof, belonging to the technical field of health care and medicine. The active ingredients of the water-soluble tomato extract comprise nucleoside compounds, flavonoid compounds and phenolic acid compounds, the water-soluble tomato extract has the effect of improving memory, can be used for preparing health-care food or medicine for improving memory, takes water as a solvent in the extraction process, is green and environment-friendly, is easy to implement, and has wide market prospect.
https://patents.google.com/patent/CN114617920A/en?q=%22water+soluble+tomato+concentrate%22&oq=%22water+soluble+tomato+concentrate%22&sort=new
It would be good to get FF added to DSM's Culterelle Probiotics (world number 1 probiotic brand). I assume it will likely go into one of their products one day.
https://culturelle.co.uk/
or some DSM BioCare customers
https://www.borderless.net/news/life-sciences/dsm-acquires-biocare-copenhagen/
https://www.biocarecph.com/en_us/about.html
CardioCare with FF
https://www.biocarecph.com/en_us/product-concepts/metabolic-health.html
BioCare C-Balance
https://www.dsm.com/content/dam/dsm/protected/human-nutrition/pre-probiotics-brochure-2021.pdf
Also we have Hologram Sciences, which I expect to launch a brand using FF some time. I feel certain they will, but when I have no idea.
Occasional one still popping up.
https://allbusinessadvice-com.translate.goog/health/233.html?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp
It seems very impressive website with very good slide show. So probably IF is doing something and gearing up for 2023. Hope we will be in profit by then.
Another article on by-health international (Australia) regarding cross border e-commerce but this one mentions provexis and fruitflow at the end wrt new product development.
https://www.nutraingredients-asia.com/Article/2021/11/29/For-the-night-owl-BYHEALTH-reports-strong-sales-of-milk-thistle-melatonin-products-in-11.11
A link to support my suggestion on e-commerce from by-health Austria.
https://www.nutraingredients-asia.com/Article/2022/02/07/BYHEALTH-securing-e-comm-success-via-distributor-empire-private-domain-management-in-China
We know by-health won't be selling any ff based products directly in China until they have regulatory approval although that doesn't stop them selling ff as an ingredient.
I wonder if they have looked at cross border e-commerce as a way of launching.
And if you take that’s with this snippet “By-Health currently expects to be in a position to complete the last of its eight studies in 2022, and it will file its regulatory submission to the SAMR for Fruitflow at the appropriate time “ to much of a coincidence in my mind , imho
Looks like IF is gearing everything Towards Jan 1st 2023. !The Company looks forward to welcoming and serving the majority of DSM's existing customers for Fruitflow from January next year, and is very pleased to be taking over control of the supply chain / production process for Fruitflow at the same time. There will be some clear synergies from January 2023 as the Company will be looking to sell Fruitflow to: (i) former DSM customers for Fruitflow; (ii) DSM and its Premix and Market-Ready Solutions businesses; (iii) new customers for Fruitflow as a straight ingredient; and (iv) By-Health and its customers, through the Company's long term supply and distribution agreement for Fruitflow with By-Health. Provexis will continue to sell its Fruitflow+ Omega-3 dietary supplement product direct to consumers, and serve its Chinese Cross-Border e-commerce distributor for this product in China. Subscriber numbers on the www.fruitflowplus.com website remain at an all-time high level.
Haemo-in-form ® fluid is a high-quality preparation that supports normal blood platelet aggregation with water-soluble tomato extract and thus contributes to healthy blood flow.
https://www.formmed-shop.de/wirkung/anwendungsgebiet/blutgerinnung/haemo-in-form-fluid?number=2000.1285
You must have a lot more respect for the work of journalism than I do.
My late friend described them as "kiddie scribblers", often with very good justification.
The 3 unknowns are why the Yahoo Fool journo used the word " Should ".
Just how long is that piece of string ?
It's an imponderable, but, as the AA will lapse, it may be indicated in future reports how much of the cake PXS received. Or it may not, disclosure would give clues to others tied in with DSM.
Production is outsourced, and production quantities have been ordered for Fruitflow+ before, so no worries in that respect. Logistics outsourcing should be equally straightforward. Sales and marketing to drive up sales, persuading larger brands to come on board is a major challenge. As you say welly, SAMR approval, followed by volume orders from By Health, would provide the basis for global expansion of marketing reach.
What will happen to DSMV in their new, merged, mega company? Another imponderable, but I see no reason for a fire sale, they still retain an important collaboration with the new, standalone, Provexis.
Tend to think all the challenges re supply chain, finance, etc. with this deal pale into insignificance post SAMR
" it is currently expected that this would result in some significant orders for Fruitflow, potentially at a multiple of current total sales values."
W$
Good thoughts BB.
As far as I can tell there are 3 unknowns that make it difficult to workout the financials after the AA
1/ The profit split. 50/50 would be a good guess as that, IMO, would be worst case for PXS under the new agreement. I had always hoped that we were getting as much as 50% of the profit but in real terms this could have been lower meaning our share of the profit under the new agreement could more than double "assuming like for like sales and margins"
2/ The royalty payable to DSM on the gross profit. This is a big unknown.
3/ The fixed level of overhead deduction from sales. Again an unknown but this obviously stops under the new agreement although we are in discussions with "third parties seeking to progress new sales and distribution opportunities" and there would be a cost to this.
My guess is the company will start to see a profit in calendar year 2023 onwards and that's without factoring in any possible sales to By-Health.
BWTFDIK. DYOR. etc. etc. etc.
fwiw - some further thoughts on the financial implications of, effectively, allowing the AA to lapse ...
For the last FY, our share of the profits was 358k, up from 235k the year previously.
For H1 of the FY 2021/2022, our share was 135k, down from 172k
Total revenue for the full FY 2021/22 was 426k, down from 505k. I would guess that most of the drop was down to a drop in the profit share from DSM, so our share of the AA might be somewhere between 250k and 300k ?
Plainly we don't know what the profit split is, but, if, for example, it was 50/50, then, all other things being equal, once the AA came to an end, we'd be looking at an extra 250 to 300k coming through to our bottom line. But all things aren't equal because we know we'll be paying a royalty to DSM based on sales / gross margin ( reducing in years 2 to 4 ), so, we should, hopefully, be pushing close to break even in calendar year 2023 ?
To add something on what Bella mentioned. We'll be responsible for maintaining the inventory on Fruitflow as an ingredient, which, while not directly affecting profitability, could, depending on how often manufacturing runs are made, give us cashflow issues. If we can manage that cashflow within our existing net cash ( roughly 900k as of end March 2022 ? ) and / or borrow against expected cashflow, then there's no need for another placing. To be honest, given what we know now, I think the million previously raised was at least partially raised for the scenario now unfolding
BB
everhopeful, am I reading the same RNS as you?
As not once is the word "should" included in it.
It does say "From 1 January 2023 the net profit accruing to Provexis on sales of Fruitflow in the calendar year - on a pro-forma basis, assuming like for like sales and margins - would be materially ahead of the net share of the profit that would have accrued to Provexis with like for like sales and margins under the existing 2010 Alliance Agreement; on the same pro-forma basis,"
wellsite, agree there are still plenty of unknowns and there are no answers to the points you highlight.
1/ DSM haven't been binned as such and will still be involved in the sale of Fruitflow along with a new partnership.
2/ Good question. I take it if they think there investment will go up from here then they will hold but if the want to invest in another Co then who knows.
3/ Depends on the patent and results of the study. DSM are interested in it.
4/ The million dollar question is when.
gix
personally feel we are in limbo.
1/ Did we bin DSM or did DSM bin us. Erring on the former - what do they say doing the same and expecting a different outcome is a sign of ?
2/ What will happening to DSMV shares - hold, fire sale or transfer
3/ New Patent - we've already got loads of patents, will one more make any difference
4/ SAMR outcome
All of the above SP changing unknowns shall be answered before profit comes in, plenty of time to trade.
WS
"Says the agreements should lead to a substantial increase annual sales and net profit."
"Should" , if DSM couldn't get more sales and were happy to let go then it doesn't smell of roses. I am hoping BH have said that they don't like the agreement as it muddies the waters for M&A.
Strangely quiet here (Volume wise) considering the recent news and the fact that we could start seeing a profit from 1/1/2023 onwards.